Novocure Ltd (NVCR)

[Getitgogone]

Novocure Announces Webcast to Discuss New EF-14 Clinical Trial Analyses and Tumor Treating Fields Presentations from SNO 2015

St. Helier, Jersey – Nov. 17, 2015 – Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today that it will hold a webcast on Monday, Nov. 23, 2015, beginning at 4:30 p.m. EST to discuss the new EF-14 analyses and Tumor Treating Fields (TTFields) presentations from the 20th Annual Meeting of the Society of Neuro-Oncology.

The new EF-14 clinical trial analyses to be presented at SNO and that will be discussed during the webcast show the use of TTFields therapy with temozolomide did not adversely affect newly diagnosed GBM patients’ quality of life; and, GBM patients who continued TTFields therapy in combination with chemotherapy, including bevacizumab, at first recurrence lived longer than patients who received chemotherapy alone.

Analysts and investors can participate in the conference call by dialing [phone] for domestic callers and [phone] for international callers, using the conference ID 81604390. Access the webcast live from the Investor Relations page of Novocure’s website, where it will be available for replay for 14 days following the call.


http://www.novocure.com/news-and-events/news/2015/11-17-2015.aspx